SCHEMBL823338

SCHEMBL823338

[C-]#[N+]c1c[nH]n2c(=O)c(O)c(C(=O)NCc3ccc(F)cc3)nc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
HSD17B10 Q99714 2/20 0.51
ERCC1 P07992 1/20 0.44
FEN1 P39748 1/20 0.44
ERCC4 Q92889 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
KCNE1 P15382 1/20 0.42
CCR1 P32246 1/20 0.42
KCNQ1 P51787 1/20 0.42
KCNH2 Q12809 1/20 0.42
CYP2C9 P11712 1/20 0.42
TP53 P04637 1/20 0.41
POLB P06746 1/20 0.41
MAPT P10636 1/20 0.41
BLM P54132 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
LIPG Q9Y5X9 1/20 0.39
LMNA P02545 1/20 0.39
CALCA P06881 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL823337 0.85 MEN1 (0.42) MEN1KMT2AHSD17B10MAPTBLM
SCHEMBL12952647 0.85 MEN1 (0.53) MEN1KMT2AHSD17B10ERCC1FEN1
SCHEMBL825990 0.82 KDM5A (0.55) MEN1KMT2AHSD17B10ERCC1FEN1
SCHEMBL823345 0.78 KCNE1 (0.45) MEN1KMT2AHSD17B10ERCC1FEN1
SCHEMBL823561 0.76 SMN1; SMN2 (0.54) MEN1KMT2AHSD17B10ERCC1FEN1
SCHEMBL823335 0.74 SMN1; SMN2 (0.43) KMT2AERCC1FEN1ERCC4SMN1; SMN2
SCHEMBL823497 0.71 SMN1; SMN2 (0.52) MEN1KMT2AERCC1FEN1ERCC4
SCHEMBL4555867 0.71 SMN1; SMN2 (0.48) MEN1KMT2AHSD17B10ERCC1FEN1
SCHEMBL1886479 0.70 THRB (0.57) MEN1KMT2AERCC1FEN1ERCC4
SCHEMBL12952653 0.70 SMN1; SMN2 (0.47) MEN1KMT2AHSD17B10ERCC1FEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143268-B2 Bicyclic pyrimidinones and uses thereof AVEXA LIMITED (AU) 2012-03-27 US disclosed
US-20100168063-A1 BICYCLIC PYRIMIDINONES AND USES THEREOF AVEXA LIMITED (AU) 2010-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168063-A1 BICYCLIC PYRIMIDINONES AND USES THEREOF TPMT, TYMP, DPYD MEN1 1774/4885KMT2A 2241/4885HSD17B10 1416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.